⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of MolPE AI (分子势能) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
MolPE AI (分子势能)
↗Shanghai, China
MolPE AI is a technology company focused on accelerating drug discovery through artificial intelligence. They provide a modular 'MolPE BioX' platform that integrates reinforcement learning for target discovery and dual-stage molecular generation, aiming to shorten R&D cycles and reduce costs for pharmaceutical and biotech companies.
The company offers both a software platform and customized consulting services to assist in the digital transformation of drug R&D processes. Their technology has been validated through collaborations with institutions such as Peking University and West China Hospital, focusing on areas like antibody design, target identification, and preclinical optimization.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:
Industry:Digital Health
Sub-Industry:AI-driven drug discovery platform
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
PIPELINE
Stage:Discovery
Lead Drug Stage:N/A (Platform provider)
Modalities:Antibodies, Small molecule, Cell therapy, Gene therapy
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Peking University (Validation), West China Hospital (Validation)
COMPETITION
Position:Emerging
Competitors:Insilico Medicine, Schrödinger, Exscientia
LINKS
Website:molpeai.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with MolPE AI (分子势能). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.